Hoffman Estates, Illinois 60169

  • Corneal Ectasia


The primary objective of this study is to determine the effectiveness and safety of corneal collagen cross-linking at irradiance levels of 9 and 18 mW/cm2.


General Inclusion Criteria Prospective subjects must meet all of the following criteria to be eligible for participation: - 18 years of age or older - Signed written informed consent - Willingness and ability to comply with schedule for follow-up visits - Contact lens removal prior to evaluation and treatment Inclusion criteria for progressive keratoconus Prospective subjects must meet two of the following criteria: - Having a diagnosis of progressive keratoconus: - An increase of ≥ 1.00 D in the steepest keratometry value - An increase of ≥ 1.00 D in astigmatism manifest refraction - A myopic shift (decrease in the spherical equivalent) of ≥ 0.50 D on subjective manifest refraction - Presence of central or inferior steepening on the Pentacam map. - Axial topography consistent with keratoconus - Steepest keratometry (Kmax) value ≥ 47.00 D Inclusion criteria for ectasia Prospective subjects must meet the following criteria: - History of having undergone a keratorefractive procedure - Meeting two of the following criteria - Steepening by topography, either Pentacam or Humphrey - Thinning of cornea - Shift in the position of thinnest portion of cornea - Change in refraction with increasing myopia - Development of myopic astigmatism - Development of irregular astigmatism - Loss of best spectacle corrected acuity. 6.2 Exclusion Criteria Subjects meeting any of the following criteria will be excluded from this protocol: - Eyes classified as either normal, atypical normal, - Corneal pachymetry ≤ 350 microns at the thinnest point measured by Pentacam in the eye to be treated - A history of chemical injury or delayed epithelial healing in the eye to be treated. - Pregnancy (including plan to become pregnant) or lactation during the course of the study - A known sensitivity to study medications - Patients with nystagmus or any other condition that would prevent a steady gaze during the treatment - Inability to cooperate with diagnostic tests. - Patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing. - Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking treatment. - Patients who are unable to remain supine and tolerate a lid speculum for an extended period of time.



Primary Contact:

Principal Investigator
Robert J Mack, M.D.
Mack Eye Center

Robert J Mack, M.D.
Phone: 847-755-9393
Email: rjsmack@aol.com

Backup Contact:


Location Contact:

Hoffman Estates, Illinois 60169
United States

Adam Baruch
Phone: 847-755-9393
Email: adam@mackeyecenter.com

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.